Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 18/20 | 0.68 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | CLK3 | P49761 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714858 | 1.00 | ITK (0.68) | ITKCLK2CLK3DYRK1ACYP19A1 | |
| SCHEMBL18426816 | 0.87 | CLK2 (0.60) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL29714863 | 0.86 | CLK3 (0.54) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL29714867 | 0.86 | CLK2 (0.63) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18426533 | 0.86 | CLK3 (0.54) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18426815 | 0.86 | CLK2 (0.63) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18453110 | 0.84 | ITK (0.47) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL29714876 | 0.83 | ITK (0.68) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL18426971 | 0.83 | ITK (0.68) | ITKCLK2CLK3DYRK1A | |
| SCHEMBL145584 | 0.82 | ITK (1.00) | ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197523-A1 | MOTORIZED INJECTION SYSTEM AND METHODS OF USE | MEIRAGTX UK II LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| CN-114728132-A | Injection system and method of use | 梅拉格特克斯治疗学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-10105370-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180256588-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-09-13 | — | — | US | disclosed |
| US-20180214428-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-02 | — | — | US | disclosed |
| US-20180214428-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2018-08-02 | — | — | US | disclosed |
| EP-3305073-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | Samumed, LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9855272-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170202846-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-07-20 | — | — | US | disclosed |
| WO-2017023973-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-9067939-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150045360-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2015-02-12 | — | — | US | disclosed |
| US-8901150-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140323479-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2014-10-30 | — | — | US | disclosed |
| US-8846714-B2 | 1H-pyrazolo[3,4-β]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8815897-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2013-11-07 | — | — | US | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20150045360-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20140323479-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20170202846-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
| US-10105370-B2 | 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20180214428-A1 | 3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | ITK 1674/4885CLK2 1502/4885CLK3 1500/4885 |
| US-20180256588-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | ITK 1527/4885CLK2 2380/4885CLK3 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.